These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
518 related articles for article (PubMed ID: 29357916)
1. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms. Wagner J; Kline CL; Zhou L; Khazak V; El-Deiry WS J Exp Clin Cancer Res; 2018 Jan; 37(1):11. PubMed ID: 29357916 [TBL] [Abstract][Full Text] [Related]
2. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model. Ding C; Li L; Yang T; Fan X; Wu G BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020 [TBL] [Abstract][Full Text] [Related]
3. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model. Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037 [TBL] [Abstract][Full Text] [Related]
4. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner. Prabhu VV; Allen JE; Dicker DT; El-Deiry WS Cancer Res; 2015 Apr; 75(7):1423-32. PubMed ID: 25712124 [TBL] [Abstract][Full Text] [Related]
5. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90α in human colorectal cancer. Lee SJ; Lee I; Lee J; Park C; Kang WK Br J Cancer; 2014 Jul; 111(3):497-505. PubMed ID: 24945998 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model. Mueller T; Freystein J; Lucas H; Schmoll HJ Molecules; 2019 Aug; 24(16):. PubMed ID: 31394786 [TBL] [Abstract][Full Text] [Related]
8. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor. Mésange P; Poindessous V; Sabbah M; Escargueil AE; de Gramont A; Larsen AK Oncotarget; 2014 Jul; 5(13):4709-21. PubMed ID: 25015210 [TBL] [Abstract][Full Text] [Related]
9. FOXF1 promotes angiogenesis and accelerates bevacizumab resistance in colorectal cancer by transcriptionally activating VEGFA. Wang S; Xiao Z; Hong Z; Jiao H; Zhu S; Zhao Y; Bi J; Qiu J; Zhang D; Yan J; Zhang L; Huang C; Li T; Liang L; Liao W; Ye Y; Ding Y Cancer Lett; 2018 Dec; 439():78-90. PubMed ID: 30253191 [TBL] [Abstract][Full Text] [Related]
10. The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer. Inglis DJ; Lavranos TC; Beaumont DM; Leske AF; Brown CK; Hall AJ; Kremmidiotis G Cancer Biol Ther; 2014; 15(11):1552-60. PubMed ID: 25482941 [TBL] [Abstract][Full Text] [Related]
11. 4'-hydroxywogonin inhibits colorectal cancer angiogenesis by disrupting PI3K/AKT signaling. Sun D; Zhang F; Qian J; Shen W; Fan H; Tan J; Li L; Xu C; Yang Y; Cheng H Chem Biol Interact; 2018 Dec; 296():26-33. PubMed ID: 30217479 [TBL] [Abstract][Full Text] [Related]
13. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma. Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514 [TBL] [Abstract][Full Text] [Related]
14. mTOR inhibition sensitizes ONC201-induced anti-colorectal cancer cell activity. Jin ZZ; Wang W; Fang DL; Jin YJ Biochem Biophys Res Commun; 2016 Sep; 478(4):1515-20. PubMed ID: 27565731 [TBL] [Abstract][Full Text] [Related]
15. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts. Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080 [TBL] [Abstract][Full Text] [Related]
16. Anti-angiogenic treatment (Bevacizumab) improves the responsiveness of photodynamic therapy in colorectal cancer. Peng CL; Lin HC; Chiang WL; Shih YH; Chiang PF; Luo TY; Cheng CC; Shieh MJ Photodiagnosis Photodyn Ther; 2018 Sep; 23():111-118. PubMed ID: 29894822 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of VEGF induces cellular senescence in colorectal cancer cells. Hasan MR; Ho SH; Owen DA; Tai IT Int J Cancer; 2011 Nov; 129(9):2115-23. PubMed ID: 21618508 [TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Wagner J; Kline CL; Ralff MD; Lev A; Lulla A; Zhou L; Olson GL; Nallaganchu BR; Benes CH; Allen JE; Prabhu VV; Stogniew M; Oster W; El-Deiry WS Cell Cycle; 2017 Oct; 16(19):1790-1799. PubMed ID: 28489985 [TBL] [Abstract][Full Text] [Related]
19. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells. Talekar MK; Allen JE; Dicker DT; El-Deiry WS Cell Cycle; 2015 Aug; 14(15):2422-8. PubMed ID: 26030065 [TBL] [Abstract][Full Text] [Related]
20. Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. Prabhu VV; Talekar MK; Lulla AR; Kline CLB; Zhou L; Hall J; Van den Heuvel APJ; Dicker DT; Babar J; Grupp SA; Garnett MJ; McDermott U; Benes CH; Pu JJ; Claxton DF; Khan N; Oster W; Allen JE; El-Deiry WS Cell Cycle; 2018; 17(4):468-478. PubMed ID: 29157092 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]